MannKind Corp
MNKD
S$4.92
Share price
-3.54%
Change (1 day)
-37.02%
Change (1 year)
Categories
Revenue for MannKind Corp (MNKD)
Revenue in 2025 (TTM): S$0.39 Billion
According to MannKind Corp's latest financial reports the company's current revenue (TTM 
) is S$0.38 Billion. In 2024 the company made a revenue of S$0.38 Billion an increase over the revenue in the year 2023 that were of S$0.26 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for MannKind Corp from 2009 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | S$0.39 B | 2.49% |
| 2024 | S$0.38 B | 47.69% |
| 2023 | S$0.26 B | 96.46% |
| 2022 | S$0.13 B | 31.14% |
| 2021 | S$0.10 B | 18.34% |
| 2020 | S$86.18 M | 1.41% |
| 2019 | S$84.98 M | 123.3% |
| 2018 | S$38.05 M | 142.28% |
| 2017 | S$15.7 M | -93.79% |
| 2016 | S$0.25 B | |
| 2015 | N/A | |
| 2014 | N/A | |
| 2013 | N/A | -100% |
| 2012 | S$0.04 M | -33.9% |
| 2011 | S$0.06 M | -45.95% |
| 2010 | S$0.11 M | |
| 2009 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Halozyme Therapeutics HALO | S$1.39 B | 264.36% | 🇺🇸 USA |
 Novo Nordisk NVO | S$56.30 B | 14,594.59% | 🇩🇰 Denmark |
 Merck MRK | S$82.30 B | 21,379.53% | 🇺🇸 USA |
 Eli Lilly LLY | S$63.09 B | 16,366.41% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | S$0.11 B | -70.68% | 🇺🇸 USA |
 Pfizer PFE | S$80.42 B | 20,889.26% | 🇺🇸 USA |